Diaceutics lifted as it exceeds expectations

0 mins. to read
Diaceutics lifted as it exceeds expectations
Master Investor Magazine

Master Investor Magazine 58Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

The share price of AIM-listed data analytics business Diaceutics (LON:DXRX) improved by 11.72% to 113.95p (as of 14:30 GMT) after revenues for the year ended 31st December climbed by 28%. Adjusted EBITDA was also ahead of expectations as it rose by 40% over the period.

CEO Peter Keeling commented: “We are pleased to have delivered on both our operational and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Group. 2019 was a key year in expanding our global footprint and deepening our service relationships with key clients and their therapy brands. These results provide a solid base for 2020 and the launch of our Nexus platform later in 2020“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *